Sherene Loi, MD, PhD, and Roberto Salgado, MD, PhD, both of the Peter MacCallum Cancer Centre, discuss study findings on pembrolizumab and trastuzumab in patients with trastuzumab-resistant disease (Abstract GS2-06).
Sibylle Loibl, MD, PhD, of the German Breast Group, discusses a study evaluating palbociclib plus endocrine treatment vs a chemotherapy-based treatment strategy in patients with hormone receptor–positive, HER2-negative metastatic breast cancer (Abstract OT3-05-04).
Debu Tripathy, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III study findings on first-line ribociclib vs placebo with goserelin and tamoxifen or a nonsteroidal aromatase inhibitor in premenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer (Abstract GS2-05).
Richard G. Gray, MSc, of the University of Oxford, discusses an Early Breast Cancer Trialists’ Collaborative Group meta-analysis of 21,000 women in 16 randomized trials, which showed that increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or sequentially administering treatment significantly reduces disease recurrence and breast cancer mortality (Abstract GS1-01).
Michael Gnant, MD, of the Medical University of Vienna, discusses phase III study findings on giving an additional 2 vs an additional 5 years of anastrozole after the first 5 years of adjuvant endocrine therapy (Abstract GS3-01).
Wolfgang Janni, MD, PhD, of Ulm University, discusses study findings that showed extended adjuvant bisphosphonate treatment over 5 years in early breast cancer does not improve disease-free and overall survival when compared with 2 years of treatment (Abstract GS1-06).
